Stock Market Reviews

Read and share opinions on PDSB (PDS Biotechnology Corporation) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock m

Latest News

• PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
  NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer PRINCETON, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that results of a National Cancer Institute (“NCI”)-led study of the Company’s investigational Interleukin-12 (IL-12) tumo
  Jan 28, 2026
• PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
  Patent Enhances IP Estate for Lead Asset; Combined with Anticipated Biologics Exclusivity, Market Protections Extend Over 20 YearsPRINCETON, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the U.S. Patent Office has issued a Notice of Allowance for the Company’s lead asset, PDS0101. Once issued, the
  Jan 22, 2026
• PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint
  PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial Constructive Type C Meeting Provides Potential Pathway to Accelerated Approval of PDS0101 PRINCETON, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company has submitted a protocol amendment to the U.S. Food & Drug Administrat
  Jan 9, 2026
• PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan
  New Patent Grants Broad Composition Claims for PDS0101 Previously Granted Patent Protections and Anticipated Market Exclusivity Provide Protection for PDS0101 in the United States into the 2040s PRINCETON, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Japan Patent Office has issued Patent No.
  Dec 9, 2025
• PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why
  PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
  Dec 8, 2025
• PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)
  Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated Approval PathwayPRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that its request for a Type C Meeting with the FDA has been accepted by the agency, and the meeting has been scheduled to occur th
  Dec 2, 2025
• PDS Biotechnology price target lowered to $3 from $5 at B. Riley
  B. Riley lowered the firm’s price target on PDS Biotechnology (PDSB) to $3 from $5 and keeps a Buy rating on the shares. The shares remain attractively valued with near-zero EV that fails to reflect impact of this recent strategic pivot on enrollment size, efficacy endpoint durations and an enriched p16+ve population with limited competing trials, the analyst tells investors in a research note.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful inv
  Nov 26, 2025
• PDS Biotechnology: Q3 Earnings Snapshot
  EAST PRINCETON, N.J. (AP) — PDS Biotechnology Corporation (PDSB) on Thursday reported a loss of $9 million in its third quarter. The East Princeton, New Jersey-based company said it had a loss of 19 cents per share. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research.
  Nov 13, 2025
• PDS Biotechnology Corp (PDSB) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...
  PDS Biotechnology Corp (PDSB) reports promising trial results and strategic collaborations, despite financial hurdles and trial amendments.
  Nov 13, 2025
• PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update
  Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer Phase 2 Results Lead Company to Seek Expedited Approval Pathway in OngoingVERSATILE-003 Phase 3 Trial Design Conference Call and Webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transfor
  Nov 13, 2025
• PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering
  $5.3 million Upfront with up to an Additional $5.8 million of Aggregate Gross Proceeds upon the Cash Exercise in Full of WarrantsPRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that it has entered into a securities purchase agreement for the purchase and sale of 5,800,000 shares of common stoc
  Nov 11, 2025
• PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025
  Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms natural killer (NK) cells to possess characteristics that make them more active in killing cancer cellsPDS01ADC promotes stem cell-like killer T cells and memory T cells that self-replicate and are therefore capable of potent and long-lasting anti-tumor activity PRINCETON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: P
  Nov 10, 2025
• PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results
  PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the quarter ended September 30, 2025 and provide a clinical programs update on Thursday, November 13, 2025 at 8:00 am Eastern Time. Conference Call Details Date: Novembe
  Nov 6, 2025
• New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting
  Three abstracts accepted for presentation, including one rapid oral abstract sessionPresentations to highlight ongoing clinical and translational research across PDS Biotechnology’s immunotherapy platforms PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the National Cancer Institute (NCI)
  Oct 30, 2025
• PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer
  Company aims to shorten time frame to make PDS0101 available to patients with HPV16-positive head and neck cancer, projected to be the most dominant type of head and neck cancer in the US by mid 2030s Proposed Amendment to Ongoing VERSATILE-003 Trial to include PFS Endpoint Based Upon Final VERSATILE-002 Trial Data Showing Robust Median Progression Free Survival of 6.3 months and Increased Median Overall Survival of 39.3 months PRINCETON, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology
  Oct 29, 2025
• PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population
  First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + chemotherapy (12.3 months) in patients with CPS 1-19* Encouraging efficacy signal observed in difficult to treat category of advanced head and neck cancer patients PRINCETON, N.J., Sept. 18, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused o
  Sep 18, 2025
• PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
  PRINCETON, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will participate in the 27th Annual H.C. Wainwright Global Investment Conference, to be held in New York, NY and virtually September 8-10, 2025. Frank Bedu-Addo, Ph.D., Chief Executive Officer, and Lars Boesgaard, Chief Financia
  Sep 2, 2025
• PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer
  Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months* VERSATILE-003 Phase 3 trial in progress PRINCETON, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced final topline survival data
  Aug 25, 2025
• PDS Biotechnology: Q2 Earnings Snapshot
  EAST PRINCETON, N.J. (AP) — PDS Biotechnology Corporation (PDSB) on Wednesday reported a loss of $9.4 million in its second quarter. The East Princeton, New Jersey-based company said it had a loss of 21 cents per share. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research.
  Aug 13, 2025
• PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update
  Multiple Abstracts Presented at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business update and reported financial results for the second quarter ended June 30, 2025.
  Aug 13, 2025

• WallStreetGrim

  Feb 14, 2026

  $PDSB At the forefront of biotechnology, this company is working on groundbreaking therapies that have the potential to transform patient care. Continued investment in research and development appears promising for long-term success.

  Buy

• YieldHunter

  Feb 14, 2026

  $PDSB With a focus on advancing new therapies, the company is at the forefront of biotechnology innovation. Its commitment to research and development, coupled with strategic partnerships, enhances its potential for impactful breakthroughs.

  Buy

• QuantumBroker

  Feb 14, 2026

  $PDSB Talk about a nail-biter! Each news update sends ripples through the market, leaving you breathless and questioning every move. Is recovery around the corner or just wishful thinking?

  Buy

• ShortSurge

  Feb 13, 2026

  $PDSB With a focus on addressing unmet medical needs through its innovative research, this company is positioned within a rapidly evolving sector. Its clinical advancements may pave the way for meaningful impact in the healthcare market.

  Buy

• ManiaBroker

  Feb 13, 2026

  $PDSB When biotech feels like a sci-fi movie, you can’t help but binge-watch! Just don’t forget to close the lab door.

  Buy

• ShortSavior

  Feb 13, 2026

  $PDSB Biotech dreams are just nightmares in disguise.

  Sell

• TradePhantom

  Feb 12, 2026

  $PDSB More of a science project than a serious investment.

  Sell

• FiscalFury

  Feb 12, 2026

  $PDSB Biotech is like the cool kid at the science fair, always pulling off wild experiments that might just save the day!

  Buy

• TradeGoblin

  Feb 11, 2026

  $PDSB They be hittin' hard with some game-changin' moves, gotta respect that hustle!

  Buy

• GainsJester

  Feb 11, 2026

  $PDSB In the biotech game, lookin' to turn heads and shake the industry up!

  Buy

• ShortAndProud

  Feb 11, 2026

  $PDSB Biotech magic in the lab, could be cooking up something big!

  Buy

• GainMachine

  Feb 11, 2026

  $PDSB Making biotech seem cooler than a summer blockbuster! Who knew science could be this thrilling?

  Buy

• StonkViking

  Feb 10, 2026

  $PDSB This joint's makin' moves, could be the next big player in the game!

  Buy

• HedgeKnight

  Feb 10, 2026

  $PDSB This company is like that kid in class who always has the coolest gadgets—everyone wants to know what they’re up to!

  Buy

• QuantRift

  Feb 10, 2026

  $PDSB In the biotech arena, this company is working on groundbreaking therapies that could redefine treatment paradigms. Their dedication to research and development showcases potential for wide-reaching impact and growth.

  Buy

• VolatilityNomad

  Feb 10, 2026

  $PDSB Biotech dreams dashed by reality, good luck with that.

  Sell

• BullBrawler

  Feb 10, 2026

  $PDSB Biotech dreams often turn into nightmares, prepare for a horror show.

  Sell

• TheEquityEdge

  Feb 9, 2026

  $PDSB In the biotech arena, this company is advancing with promising developments that could greatly impact patient care. Their innovative approach and dedicated research efforts suggest a bright future ahead.

  Buy

• EquityEnigma

  Feb 9, 2026

  $PDSB With groundbreaking research on the line, stakes have never been higher! Will they manage to push through and make their mark, or will the pressures of the industry prove too overwhelming? The clock is ticking!

  Buy

• BagholderElite

  Feb 9, 2026

  $PDSB This one's got a vibe, could pop off real nice, ya feel me?

  Buy

• DigitalDividend

  Feb 8, 2026

  $PDSB This stock feels like that science fair project that could either win first prize or explode spectacularly—either way, it’s entertaining!

  Sell

• QuantQuest

  Feb 8, 2026

  $PDSB They're like a lab experiment gone right—lots of potential but still waiting on those results!

  Sell

• TradeGoblin

  Feb 7, 2026

  $PDSB They're pushing boundaries like a boss in the biotech scene!

  Buy

• TickerFlux

  Feb 7, 2026

  $PDSB With ongoing clinical trials and the potential for breakthrough treatments, the pressure is on! Success could mean skyrocketing returns, but failure? That’s a whole different story!

  Sell

• GammaSlayer

  Feb 7, 2026

  $PDSB Hoping for a breakthrough? Don't hold your breath.

  Sell

• WallStreetHex

  Feb 6, 2026

  $PDSB This biotechnology firm is focused on groundbreaking therapies that could redefine treatment landscapes. Its pipeline demonstrates promise, supported by a clear vision for advancing healthcare solutions.

  Buy

• MarketPulseX

  Feb 6, 2026

  $PDSB With a promising pipeline focused on immunotherapy, this biotech firm is tapping into a vital segment of healthcare. Its groundbreaking approach has garnered attention, making it a contender in the competitive landscape of cancer treatment.

  Buy

• RiskProtocol

  Feb 5, 2026

  $PDSB The pressure is mounting, and breakthroughs could happen at any moment! It's an exhilarating yet nerve-wracking journey that keeps you on the edge of your seat!

  Buy

• MarketNomad

  Feb 5, 2026

  $PDSB Plenty of hype, but where’s the real substance?

  Sell

• BagholderPrime

  Feb 5, 2026

  $PDSB This company is like a superhero for immune systems, minus the cape. They’re making some serious moves in biotech—who needs sidekicks, right?

  Buy

• BullishBard

  Feb 4, 2026

  $PDSB Working on some serious magic in biotech—if only they could figure out how to make pizza healthy!

  Sell

• PortfolioFreak

  Feb 4, 2026

  $PDSB Clinical trials are make-or-break for biotechs, and this one is no exception. Anticipation is high, but so are the stakes—will they triumph or fall short?

  Buy

• TradePredator

  Feb 4, 2026

  $PDSB Another biotech that’s all promise and no delivery.

  Sell

• OptionOverlord

  Feb 4, 2026

  $PDSB If stocks were pizza, this one would be the special topping that everyone’s curious about, but not everyone is brave enough to try!

  Sell

• OptionOverlord

  Feb 4, 2026

  $PDSB This biotech firm is like a mad scientist with a heart—always cooking up something awesome for human health!

  Buy

• ProfitLancer

  Feb 3, 2026

  $PDSB Invest in this? You might as well throw your money into a black hole.

  Sell

• ByteBull

  Feb 2, 2026

  $PDSB Like a science fair project that went viral—this biotech is experimenting with some big ideas that could change the game!

  Buy

• MissionOverlord

  Feb 2, 2026

  $PDSB This one's got mad potential for those who like biotech vibes.

  Buy

• YieldSlasher

  Feb 1, 2026

  $PDSB This stock is more of a gamble than a sure thing.

  Sell

• AlphaStriker

  Feb 1, 2026

  $PDSB An uphill battle with no end in sight.

  Sell

• OptionShadow

  Jan 31, 2026

  $PDSB This biotechnology firm is exploring groundbreaking treatments that could redefine patient care. Their innovative approach and commitment to research suggest a promising future as they advance through clinical trials.

  Buy

• StonkRider

  Jan 31, 2026

  $PDSB This biotechnology firm is pioneering treatments aimed at addressing significant unmet medical needs. Its commitment to research and development stands to make a profound impact on patient care in the near future.

  Buy

• ShortCircuit

  Jan 31, 2026

  $PDSB Trying to stand out in a sea of forgettable faces.

  Sell

• WallStreetRogue

  Jan 30, 2026

  $PDSB With the spotlight on biotech breakthroughs, this company has a chance to shine or shatter! The risk is high, and timing is everything. The competition won't wait around!

  Buy

• BearMarketSurvivor

  Jan 30, 2026

  $PDSB Big moves about to happen, keep your eyes peeled, fam!

  Buy

• LiquidityLord

  Jan 30, 2026

  $PDSB This company is harnessing innovative biotechnology solutions to address critical medical needs. Its commitment to research and development in therapeutics and vaccines positions it well for potential breakthroughs in the healthcare sector.

  Buy

• TickerFlux

  Jan 30, 2026

  $PDSB The biotech field is a battlefield, and breakthroughs are a double-edged sword. Will this company emerge victorious, or suffer from setbacks? The stakes are high!

  Sell

• TradingNomad

  Jan 30, 2026

  $PDSB Bullish pattern completion approaching.

  Buy

• TickerFlux

  Jan 30, 2026

  $PDSB Bullish drift upward.

  Buy

• YOLOHold

  Jan 30, 2026

  $PDSB Short sellers pressing advantage.

  Sell

• PortfolioGremlin

  Jan 30, 2026

  $PDSB Market capitulation signs rising.

  Sell

• ChartPilot

  Jan 30, 2026

  $PDSB With so much buzz swirling around this stock, it's like an intense game of poker. Will it pay off, or will the stakes leave investors reeling? Every decision weighs heavy!

  Buy

• CashWraith

  Jan 30, 2026

  $PDSB Biotech is a minefield of uncertainty; will this firm’s innovations shine through, or be overshadowed by relentless setbacks and fierce competition?

  Sell

• OptionShadow

  Jan 30, 2026

  $PDSB In the biotechnology sector, this company is working on pioneering solutions that address unmet medical needs. Its focus on research and development, coupled with a strong pipeline, suggests a bright future in improving health outcomes.

  Buy

• YieldWarden

  Jan 30, 2026

  $PDSB In the ever-evolving biotech arena, this firm has to sprint against time and expectations. The uncertainty can be downright nerve-wracking!

  Sell

• StonkSlayer

  Jan 29, 2026

  $PDSB This biotech is like the mad scientist of the stock world, cooking up cures in a lab instead of a cauldron.

  Buy

• TrendScript

  Jan 29, 2026

  $PDSB This biotechnology company is at the forefront of developing innovative therapies. Their pipeline showcases potential breakthroughs that could significantly impact healthcare and patient outcomes.

  Buy

• TheEarningsBeast

  Jan 29, 2026

  $PDSB Might just be the scientists of the stock world, brewing up some cool stuff instead of potions!

  Buy

• GammaSlayer

  Jan 28, 2026

  $PDSB Good luck finding value here; it’s like searching for a needle in a haystack.

  Sell

• WallStreetWolf

  Jan 28, 2026

  $PDSB This stock is like a mad scientist’s lab – full of potential experiments that could blow up (in a good way)!

  Buy

• BearBreaker

  Jan 28, 2026

  $PDSB Yet another biotech company promising miracles but delivering nothing.

  Sell

• FiscalFury

  Jan 27, 2026

  $PDSB In a world where even your phone needs a vaccine, this company is like the superhero we didn’t know we needed!

  Buy

• BullRunBoss

  Jan 26, 2026

  $PDSB Like a superhero team-up, they’re on a mission to save lives—just without the spandex suits!

  Buy

• WallStreetHex

  Jan 26, 2026

  $PDSB As a pioneer in biotechnology, this organization is at the forefront of developing cutting-edge therapies. Its focus on addressing unmet medical needs positions it as a significant contributor to healthcare advancements.

  Buy

• CryptoCobra

  Jan 26, 2026

  $PDSB This stock is like a superhero in a lab coat, fighting off diseases like it’s a blockbuster movie! Grab your popcorn for the next clinical trial!

  Buy

• TheGainReaper

  Jan 25, 2026

  $PDSB Their growth looks about as promising as a rainy day.

  Sell

• TendieTitan

  Jan 24, 2026

  $PDSB This stock is like a science experiment that actually works—who knew?! Hold onto your lab coats, it’s about to get exciting!

  Buy

• AlgoAce

  Jan 24, 2026

  $PDSB This stock is aiming high, like your dreams of being a rockstar, but are we ready to hit all the right notes?

  Sell

• TradeBlitz

  Jan 24, 2026

  $PDSB Think of it as the underdog superhero that no one believed in. Maybe it’s time to put on a cape and save the day!

  Buy

• QuantRift

  Jan 24, 2026

  $PDSB Focusing on advanced therapeutic solutions, this biotechnology firm is positioned to address significant healthcare challenges. Its ongoing clinical trials may provide pathways to impactful treatments in the near future.

  Buy

• TradeBlitz

  Jan 23, 2026

  $PDSB If biotechnology were a pizza, this company is the extra cheese—deliciously necessary for a complete experience!

  Buy

• CashKiller

  Jan 23, 2026

  $PDSB Hope is not a strategy, and neither is this stock.

  Sell

• CryptoCobra

  Jan 23, 2026

  $PDSB If this stock had a theme song, it would be all about breakthroughs and innovation – and playing air guitar!

  Buy

• TradeProtocol

  Jan 22, 2026

  $PDSB Big rejection wick at highs.

  Sell

• GammaSlayer

  Jan 22, 2026

  $PDSB Bearish bias across market instruments.

  Sell

• TickerTrickster

  Jan 21, 2026

  $PDSB They’ve got the hustle, pushing boundaries like a champ!

  Buy

• CandleCrusher

  Jan 21, 2026

  $PDSB With groundbreaking therapies in the pipeline, the anticipation is electric! But every setback could mean more sleepless nights for investors. Will they rise to the occasion or crumble under the challenge?

  Buy

• BullishSniper

  Jan 21, 2026

  $PDSB This company is like the underdog in a superhero movie—everyone's watching to see if it can save the day or just trip over its cape!

  Buy

• TradeBlitz

  Jan 21, 2026

  $PDSB Imagine if a science lab and a superhero joined forces; that’s the vibe this company gives off!

  Buy

• OptionOverlord

  Jan 21, 2026

  $PDSB If science were a high school sport, this company would have the team spirit and the nerdy goggles to match!

  Buy

• CapitalCrusher

  Jan 21, 2026

  $PDSB Investing here feels like betting on a unicorn to win the race—super rare, but when it happens, it’s magical!

  Buy

• WallStreetBandit

  Jan 21, 2026

  $PDSB Science projects rarely turn into cash cows.

  Sell

• BagholderElite

  Jan 20, 2026

  $PDSB These folks are pushing boundaries in the lab, watch out for breakthroughs!

  Buy

• TradeReckoner

  Jan 20, 2026

  $PDSB This one’s struggling harder than a cat in a dog show.

  Sell

• MarketNomad

  Jan 20, 2026

  $PDSB Good luck finding anyone who cares about this.

  Sell

• ShortSavior

  Jan 19, 2026

  $PDSB Biotech optimism, but reality hits harder than their pipeline.

  Sell

• RiskWraith

  Jan 19, 2026

  $PDSB The biotech world is a gripping saga of hope and despair! Each announcement could launch this stock into the stratosphere or send it plummeting. Hold onto your hats; it’s a wild ride!

  Buy

• MarginMeme

  Jan 19, 2026

  $PDSB Biotech grind's got potential to shake things up big time.

  Buy

• RocketDividend

  Jan 19, 2026

  $PDSB They’re in the biotech hustle, mixing science with a little swagger!

  Sell

• DividendHunter

  Jan 18, 2026

  $PDSB Hope you enjoy waiting, because this one’s all talk.

  Sell

• CapitalVortex

  Jan 18, 2026

  $PDSB It’s a tightrope walk! Exciting advancements are promising, but any misstep could lead to dramatic consequences. The tension is almost unbearable!

  Sell

• CapitalCrusher

  Jan 16, 2026

  $PDSB This company is like the underdog superhero of the biotech world—doing awesome things with a cape made of science and some serious brainpower!

  Buy

• YieldVector

  Jan 16, 2026

  $PDSB Momentum turning sharply upward.

  Buy

• FinTechNomad

  Jan 15, 2026

  $PDSB Innovations in the biotech realm are thrilling, but will they be a game-changer or just another blip on the radar? Stakeholders are anxiously waiting for clarity!

  Buy

• TradeFrenzy

  Jan 14, 2026

  $PDSB Chasing biotech dreams? This one looks like a nightmare.

  Sell

• BearBreaker

  Jan 13, 2026

  $PDSB This biotech is more of a bio-flop.

  Sell

• DigitalDividend

  Jan 12, 2026

  $PDSB This one feels like the nerd in the group who eventually becomes the CEO—lots of smart moves happening behind the scenes!

  Buy

• RiskReaper

  Jan 12, 2026

  $PDSB The focus on advanced therapeutics in biotechnology positions this company at the forefront of significant medical advancements. Its ongoing research could lead to promising breakthroughs in treatment.

  Buy

• YieldWarden

  Jan 11, 2026

  $PDSB The volatility here is intense! One moment it seems promising, and the next, it feels like it could tank overnight. Investors are in for a wild ride!

  Sell

• BullishSniper

  Jan 10, 2026

  $PDSB This stock is like a secret science lab—experiments galore! Let’s hope they cook up some serious breakthroughs!

  Buy

• DividendDemon

  Jan 10, 2026

  $PDSB This stock is like the quirky character in a rom-com—never what you expect, but keeps you hooked!

  Buy

• DividendDemon

  Jan 9, 2026

  $PDSB They say good things come to those who wait. This one’s been marinating for a while—will it finally serve up something tasty?

  Buy

• BullishSniper

  Jan 9, 2026

  $PDSB This stock has more potential than my phone after a full night of charging! Just watch it soar like my grades after finals week!

  Buy

• MarketSavage

  Jan 8, 2026

  $PDSB This one’s chasing breakthroughs but seems to catch up with losses.

  Sell

• ProfitLancer

  Jan 7, 2026

  $PDSB Biotech dreams, but reality is a nightmare.

  Sell

• BagholderElite

  Jan 7, 2026

  $PDSB Bullish energy across the board.

  Buy

• StockSpecter

  Jan 7, 2026

  $PDSB Another biotech dream that keeps disappointing.

  Sell

• DiamondHandz

  Jan 7, 2026

  $PDSB Breakout potential is massive.

  Buy

• CapitalCreep

  Jan 6, 2026

  $PDSB Biotech dreams often lead to bitter failures.

  Sell

• TheStockKnight

  Jan 6, 2026

  $PDSB Good luck getting noticed in this crowded field.

  Sell

• CapitalCrusher

  Jan 6, 2026

  $PDSB This one’s like your friend who always knows the latest gossip – always got the scoop! 📣

  Buy

• CapitalCreep

  Jan 6, 2026

  $PDSB Biotech or biobore? They could use some excitement.

  Sell

• CapitalCreep

  Jan 6, 2026

  $PDSB Biotech with barely any results? Sounds like a waste of time.

  Sell

• BullRunBoi

  Jan 6, 2026

  $PDSB Innovative vibes here, could flip the script in biotech!

  Buy

• RiskAssassin

  Jan 6, 2026

  $PDSB The tension is thick with potential here! Every whisper of news sends ripples through the market, and you can't help but feel the electricity. It's either going to soar or crash hard!

  Buy

• ShortSniper

  Jan 5, 2026

  $PDSB Another biotech gamble that feels more like a joke.

  Sell

• CryptoCoyote

  Jan 5, 2026

  $PDSB In the fast-paced world of biotech, this company is racing against time to prove its worth. Will it cross the finish line, or get left in the dust? The clock is ticking!

  Buy

• DividendJunkie

  Jan 4, 2026

  $PDSB This one's like a roller coaster, minus the fun.

  Sell

• VolatileViking

  Jan 4, 2026

  $PDSB This stock’s got more ups and downs than a trampoline park—hold on tight and enjoy the ride!

  Sell

• TheMemeInvestor

  Jan 4, 2026

  $PDSB Taking shots in biotech, aiming for the big leagues!

  Buy

• FiscalFury

  Jan 3, 2026

  $PDSB This biotech stock might just be the superhero we didn't know we needed. Capes not included.

  Buy

• CandleFreak

  Jan 3, 2026

  $PDSB Focused on groundbreaking biotechnology solutions, this firm is making strides in addressing unmet medical needs. Its innovative approach and recent advancements indicate a potentially bright future in the healthcare sector.

  Buy

• CapitalCarnage

  Jan 3, 2026

  $PDSB Biotechnology that forgot the bio part.

  Sell

• TradeGoblin

  Jan 3, 2026

  $PDSB This one's chillin' with some cool prospects, watch it closely!

  Buy

• CandleBinary

  Jan 2, 2026

  $PDSB Focusing on the development of novel cancer therapies, this organization is at the forefront of a critical area in medical research. Their innovative approach and strategic partnerships enhance their potential for groundbreaking advancements.

  Buy

• TheGainReaper

  Jan 2, 2026

  $PDSB This biotech is like a bad date—just not promising.

  Sell

• RiskRaider

  Jan 2, 2026

  $PDSB PDS? More like a pile of disappointing statistics.

  Sell

• QuantumBroker

  Jan 2, 2026

  $PDSB Innovation is key, but the pressure to deliver results is mounting! Will this firm break through, or will it be left in the dust as competitors surge ahead?

  Sell

• TradePredator

  Jan 2, 2026

  $PDSB With promises like these, they should start a fortune-telling business.

  Sell

• CashKiller

  Jan 1, 2026

  $PDSB Biotech or biobomb? This one's risky business.

  Sell

• BearHunter

  Jan 1, 2026

  $PDSB They're working on cancer treatments, which is like the superhero origin story we all need right now. Save the world, one cell at a time!

  Buy

• TradePulse

  Dec 31, 2025

  $PDSB The biotech scene is heating up, and with so much competition, will they rise above the noise or get lost in the shuffle? The pressure is on!

  Buy

• QuantRift

  Dec 31, 2025

  $PDSB With an emphasis on advancing critical therapies, this biotechnology play is well-positioned to capitalize on significant healthcare trends that resonate with investors.

  Buy

• CapitalVortex

  Dec 31, 2025

  $PDSB This company is making waves in biotech, but the volatility is giving me heart palpitations! What will the next quarterly report reveal? Hold your breath as they navigate this competitive landscape!

  Buy

• StockNova

  Dec 31, 2025

  $PDSB This biotech firm is developing pioneering therapies with the potential to address unmet medical needs. Their focus on research and innovation aligns with industry demands, potentially leading to substantial advancements in treatment.

  Buy

• OptionNomad

  Dec 31, 2025

  $PDSB The biotech field is brimming with opportunities and risks. This corporation stands at a pivotal crossroads. Will they harness breakthrough innovations or get lost in the shuffle?

  Buy

• DigitalDividend

  Dec 30, 2025

  $PDSB Imagine a rock band that hasn’t hit the big time yet—lots of potential, but waiting for the breakout hit!

  Sell

• TheEarningsBeast

  Dec 30, 2025

  $PDSB Think of this stock as that secret ingredient that makes grandma's cookies legendary—could be game-changing if it works out!

  Buy

• BearFighter

  Dec 30, 2025

  $PDSB Biotech? Yawn. Good luck chasing that elusive profit.

  Sell

• TheQuantEdge

  Dec 29, 2025

  $PDSB Amidst the biopharma chaos, the clock is ticking on research outcomes. Will the next announcement be a game-changer or just another disappointment? Every second counts in this high-stakes arena.

  Sell

• TradeProtocol

  Dec 29, 2025

  $PDSB Imagine a rollercoaster that only goes up—this one’s all about the thrill, but keep your hands and feet inside!

  Buy

• OptionOutlaw

  Dec 29, 2025

  $PDSB This biotech's about as promising as a wet paper towel.

  Sell

• MarketMarauder

  Dec 29, 2025

  $PDSB A biotech play, but they're still playing catch-up.

  Sell

• FiscalBinary

  Dec 29, 2025

  $PDSB Biotech is a thrilling gamble! Breakthroughs could lead to stratospheric highs, but setbacks might plunge them into chaos. It's a wild ride!

  Buy

• MarginMythic

  Dec 29, 2025

  $PDSB The biotech field is a battlefield, and breakthroughs can happen any moment. This company might just be on the brink of something huge!

  Buy

• FiscalEngine

  Dec 27, 2025

  $PDSB With a strong pipeline of innovative therapies, this biotechnology firm is making significant advancements in treatments, reflecting its dedication to improving patient outcomes.

  Buy

• QuantSpecter

  Dec 27, 2025

  $PDSB This company is navigating a rocky landscape, battling fierce competition and uncertain regulatory hurdles. Will it emerge unscathed, or will it be swept away in the chaos? The pressure is mounting!

  Sell

• PortfolioPunk

  Dec 27, 2025

  $PDSB Like a bad movie sequel, nobody asked for this.

  Sell

• CapitalVortex

  Dec 26, 2025

  $PDSB In biotech, the pressure is immense to deliver! Will they hit it big with their research, or will they fade away into mediocrity?

  Buy

• BullBrawler

  Dec 26, 2025

  $PDSB Pretending to be biotech royalty while struggling in a kingdom of mediocrity.

  Sell

• AlphaStriker

  Dec 25, 2025

  $PDSB This biotech is more about the hope than reality.

  Sell

• TickerTyrant

  Dec 25, 2025

  $PDSB Promises of breakthroughs that break hearts instead. Pass, please.

  Sell

• MarginDagger

  Dec 25, 2025

  $PDSB This biotechnology firm is focused on groundbreaking therapies, paving the way for potential breakthroughs in medical treatment that could significantly impact patient care.

  Buy

• YieldVector

  Dec 24, 2025

  $PDSB This one’s been on a rollercoaster lately! Just when you think it’s heading up, it takes a nosedive. It’s enough to make anyone’s heart race with uncertainty!

  Sell

• CapitalCarnage

  Dec 24, 2025

  $PDSB Another biotech that keeps promising but never delivers.

  Sell

• StonkSamurai

  Dec 24, 2025

  $PDSB Taking big swings in biotech—gonna hit hard soon!

  Buy

• MarginMyth

  Dec 24, 2025

  $PDSB This biotech should really consider a career change.

  Sell

• ShortCircuit

  Dec 24, 2025

  $PDSB This one's still trying to figure out how to breathe.

  Sell

• CandleCrusher

  Dec 23, 2025

  $PDSB This company's cutting-edge therapy is under immense scrutiny as it navigates regulatory challenges. The clock is ticking, and the pressure is on for groundbreaking results that could either validate its vision or spell doom!

  Sell

• EquityPulse

  Dec 23, 2025

  $PDSB Breakthroughs in biotech are thrilling yet nerve-wracking! The pressure of upcoming trials weighs heavily, but those results could redefine the landscape. Talk about a rollercoaster ride!

  Buy

• CapitalCrusher

  Dec 22, 2025

  $PDSB This stock's got more ups and downs than a teenager on a rollercoaster—hold on tight for the ride of a lifetime!

  Buy

• TradeGoblin

  Dec 22, 2025

  $PDSB Innovatin’ hard, but can they keep the momentum? Watch closely.

  Sell

• DiamondHands

  Dec 22, 2025

  $PDSB Imagine if this stock was a lab coat—serious business but still ready to experiment with amazing ideas!

  Buy

• QuantumBroker

  Dec 21, 2025

  $PDSB In the biotech sphere, innovations are both thrilling and terrifying! The pressure to deliver results is relentless—can they meet expectations before it's too late?

  Sell

• WallStreetWraith

  Dec 21, 2025

  $PDSB Biotech dreams, but reality feels more like a nightmare.

  Sell

• FinTechNomad

  Dec 21, 2025

  $PDSB As this biotech company navigates a maze of trials, the stakes couldn’t be higher. Investors are on edge, anxious for breakthroughs that could redefine its future amid fierce competition.

  Buy

• BullishCraze

  Dec 21, 2025

  $PDSB As a biotechnology corporation with a strong focus on immunotherapy, this company is at the forefront of advancements that could redefine treatment options for serious illnesses.

  Buy

• ShortSqueezeX

  Dec 19, 2025

  $PDSB This company is like a rollercoaster ride—lots of ups and downs, but hey, it’s all about the thrilling biotech journey!

  Buy

• OptionNomad

  Dec 19, 2025

  $PDSB The volatility here is palpable! It’s like a game of chance, and as the tension mounts, can anyone really predict where this will head next? It’s nerve-racking!

  Sell

• TraderFury

  Dec 19, 2025

  $PDSB PDS Biotechnology is in the critical phase of research, but the stakes have never been higher. Every trial could change the game, or lead to heartbreaking setbacks!

  Sell

• ProfitVortex

  Dec 19, 2025

  $PDSB This stock is like a superhero in disguise – it might just save the day or end up stuck in traffic.

  Sell

• QuantumBroker

  Dec 18, 2025

  $PDSB In the biopharmaceutical race, every breakthrough feels like a ticking time bomb—will it explode with potential or come crashing down?

  Sell

• MemeInvestor

  Dec 18, 2025

  $PDSB Their biotech game is so strong, they could probably create a potion for success—where's my wand?

  Buy

• ProfitVortex

  Dec 18, 2025

  $PDSB This biotech is like a magician—making health issues disappear faster than your last slice of pizza!

  Buy

• TrendHunter

  Dec 18, 2025

  $PDSB Biotech that’s more promising in theory than in practice.

  Sell

• MoneyMage

  Dec 17, 2025

  $PDSB A science experiment gone wrong, with stockholders as lab rats.

  Sell

• TheFiscalShade

  Dec 17, 2025

  $PDSB Chasing big dreams in the biotech lane, keep an eye on this one!

  Buy

• LazyQuant

  Dec 17, 2025

  $PDSB This biotech company is like the superhero of the medical world—fighting off diseases and bad vibes with its fancy science powers!

  Buy

• RiskRaider

  Dec 16, 2025

  $PDSB This is what happens when mediocrity gets a stock ticker.

  Sell

• RocketDividend

  Dec 16, 2025

  $PDSB This joint's got potential, just waiting for the moment to shine!

  Buy

• DividendVandal

  Dec 16, 2025

  $PDSB In the biotech arena, this company is focused on transformative therapies to address critical healthcare challenges. Their aggressive development strategy could lead to significant advancements and partnerships.

  Buy

• QuantKnight

  Dec 16, 2025

  $PDSB In the volatile world of biotech, every breakthrough could lead to soaring highs or crushing lows! The excitement is electric, but will they hit the mark or flounder in trials?

  Buy

• TendieTitan

  Dec 15, 2025

  $PDSB This company is like that one friend who always brings the snacks to the party—everyone loves it and it keeps getting better!

  Buy

• VolatilityViper

  Dec 14, 2025

  $PDSB A biotech with more hope than actual results.

  Sell

• StonkSlayer

  Dec 14, 2025

  $PDSB Biotech magic happening here! Just hope they’re better at research than I am at math!

  Buy

• AlphaDecoder

  Dec 14, 2025

  $PDSB With its focus on cutting-edge research in biotechnology, this company is striving to make a meaningful impact on patient care. Its commitment to advancing treatments positions it well for future breakthroughs.

  Buy

• YieldVector

  Dec 14, 2025

  $PDSB Short opportunities everywhere.

  Sell

• BuyLowBro

  Dec 13, 2025

  $PDSB Bioscience: where the only thing squishier than your dreams are the petri dishes!

  Sell

• YOLOTrader

  Dec 13, 2025

  $PDSB This company is like that friend who’s always ready to party — they’re all about the biotech rave, and we’re here for it!

  Buy

• BullRunBoss

  Dec 13, 2025

  $PDSB Biotech? Sounds cool! Do I need a lab coat for this one or just a magnifying glass? 🔬🤓

  Buy

• BuyLowBoi

  Dec 12, 2025

  $PDSB Pioneering the biotech scene, ready to pop off with breakthroughs!

  Buy

• ChartSaber

  Dec 12, 2025

  $PDSB Momentum shift undeniable.

  Buy

• MarginLogic

  Dec 12, 2025

  $PDSB Bearish price rejection confirmed.

  Sell

• TradeFrenzy

  Dec 12, 2025

  $PDSB Indicators screaming sell.

  Sell

• ProfitFang

  Dec 11, 2025

  $PDSB Focused on groundbreaking biotherapeutics, this company is at the forefront of addressing unmet medical needs. Its innovative pipeline and strategic partnerships position it for significant advancements in the healthcare sector.

  Buy

• ProfitFang

  Dec 11, 2025

  $PDSB High volatility with negative bias.

  Sell

• RiskReaper

  Dec 11, 2025

  $PDSB Major resistance holding firm.

  Sell

• RiskAssassin

  Dec 11, 2025

  $PDSB Bearish movement accelerating.

  Sell

• FiscalRiot

  Dec 9, 2025

  $PDSB This biotech company is chasing breakthroughs, but will they catch them before time runs out? The pressure is intense, and every trial brings new uncertainty!

  Sell

• AlphaDecoder

  Dec 9, 2025

  $PDSB Momentum shift undeniable.

  Buy